Comparison of Transbronchial Cryobiopsy and Forceps Biopsy in Lung Transplant Recipients

Last updated: June 27, 2024
Sponsor: University of Zurich
Overall Status: Completed

Phase

N/A

Condition

N/A

Treatment

FB-CB study arm

CB study arm

Clinical Study ID

NCT05006742
ID 2021-00466
  • Ages > 18
  • All Genders

Study Summary

CLAD is defined as loss of lung function after other factors, particularly infections have been excluded. Readily accessible diagnostic procedures to detect acute cellular rejection at the earliest possible occasion is crucial for posttransplant survival. Serial lung function tests, laboratory testing and pulmonary imaging are only clinical indicators of chronic allograft dysfunction in lung transplant recipients. Since forceps biopsy to detect acute cellular rejection in lung transplant recipients has several shortcomings, the purpose of this study is to investigate a new biopsy technique using the transbronchial cryoprobe.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • routinely performed surveillance bronchoscopy and when indicated including serial FBand CB in the same session in patients wo had undergone lung transplant

  • male or female subject of at least 18 years of age

  • written informed consent after participant's information signed by patient

Exclusion

Exclusion Criteria:

  • age < 18 years

  • Lacking ability to form an informed consent (including impaired judgement,communication barriers)

  • Contraindication against bronchoscopy (e.g. co-morbidities)

  • INR > 2 or Thrombocytes < 50000

  • Double antiplatelet drugs (e.g. ASS and Clopidogrel) within 7 days before biopsy

  • Anticoagulation with NOAK within 48 hours before biopsy

  • Moderate or severe pulmonary hypertension (mPAP > 30 mmHg, RV/RA >30 mmHg)

Study Design

Total Participants: 80
Treatment Group(s): 2
Primary Treatment: FB-CB study arm
Phase:
Study Start date:
May 07, 2021
Estimated Completion Date:
February 28, 2024

Study Description

Eventually, histopathological confirmation is indispensable to establish the diagnosis of acute cellular rejection. The current gold standard for diagnosis and grading of acute cellular rejection in order to initialize the optimal treatment, with particular regard to adjusting immunosuppression, is forceps biopsy to obtain ≥ five samples. Forceps biopsy has a reasonable risk profile in experienced centers and is performed 2, 4, 6 and 12 months posttransplant and when indicated. Given these concerns about diagnostic yield in forceps biopsy and unjustifiable risks after surgical lung biopsy, cryobiopsy has arisen as promising alternative diagnostic procedure. The value of cryobiopsy to obtain a conclusive diagnosis of ACR is discussed controversially due the lack of safety and efficacy data in lung transplant recipients

Connect with a study center

  • University hospital Zurich

    Zurich, 8091
    Switzerland

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.